Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Aromatase inhibitors in premenopausal breast cancer.

Kelly CM, Buzdar AU.

Lancet Oncol. 2012 Apr;13(4):320-1. doi: 10.1016/S1470-2045(11)70399-0. Epub 2012 Jan 20. No abstract available.

PMID:
22265695
2.

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S.

Lancet Oncol. 2012 Apr;13(4):345-52. doi: 10.1016/S1470-2045(11)70373-4. Epub 2012 Jan 20.

PMID:
22265697
3.

Neoadjuvant endocrine therapy in breast cancer.

Beresford MJ, Ravichandran D, Makris A.

Cancer Treat Rev. 2007 Feb;33(1):48-57. Epub 2006 Nov 28. Review.

PMID:
17134840
4.

Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.

Krell J, Ewart EK, Stebbing J.

Eur J Cancer. 2010 Nov;46(16):2867-9. doi: 10.1016/j.ejca.2010.08.021. Epub 2010 Sep 27. No abstract available.

PMID:
20880696
5.

Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M.

J Clin Oncol. 2011 Jul 1;29(19):2653-9. doi: 10.1200/JCO.2010.33.2585. Epub 2011 May 9.

6.

The biology of steroid hormones and endocrine treatment of breast cancer.

Dowsett M, Folkerd E, Doody D, Haynes B.

Breast. 2005 Dec;14(6):452-7. Epub 2005 Sep 28. Review.

PMID:
16198110
7.

Tamoxifen therapy for patients with breast cancer - Authors' reply.

Davies C, Gray R, Pan H, Peto R; ATLAS collaborative group.

Lancet. 2013 Jun 15;381(9883):2078-9. doi: 10.1016/S0140-6736(13)61238-6. No abstract available.

PMID:
23769225
8.
9.

The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.

Mouridsen HT.

Cancer Invest. 2010;28 Suppl 1:1-3. doi: 10.3109/07357907.2010.501632. No abstract available.

PMID:
20653402
10.

Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.

Iwata H, Masuda N, Sagara Y, Kinoshita T, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Tsuda H, Hayashi N, Noguchi S.

Cancer. 2013 Feb 15;119(4):704-13. doi: 10.1002/cncr.27818. Epub 2012 Sep 12.

11.

Tamoxifen therapy for patients with breast cancer.

Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G.

Lancet. 2013 Jun 15;381(9883):2077-8. doi: 10.1016/S0140-6736(13)61236-2. No abstract available.

PMID:
23769223
12.

Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.

Yao S, Xu B, Li Q, Zhang P, Yuan P, Wang J, Ma F, Fan Y.

Endocr J. 2011;58(6):509-16. Epub 2011 Apr 29.

13.

Letrozole in the neoadjuvant setting: the P024 trial.

Ellis MJ, Ma C.

Breast Cancer Res Treat. 2007;105 Suppl 1:33-43. Epub 2007 Oct 3. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):371.

14.

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.

Nishimura R, Anan K, Yamamoto Y, Higaki K, Tanaka M, Shibuta K, Sagara Y, Ohno S, Tsuyuki S, Mase T, Teramukai S.

Oncol Rep. 2013 May;29(5):1707-13. doi: 10.3892/or.2013.2312. Epub 2013 Feb 27.

15.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.

PMID:
18718815
16.

Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

Buzdar A.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S42-8. Review.

PMID:
12756078
17.

Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.

Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JF, Winterbottom L.

Eur J Cancer. 2010 Nov;46(16):2936-42. doi: 10.1016/j.ejca.2010.08.005. Epub 2010 Sep 9.

PMID:
20832294
18.

Preliminary data from ongoing adjuvant aromatase inhibitor trials.

Goss PE.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4397s-4401s; discussion 4411s-4412s. Review.

PMID:
11916231
19.

[A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].

Baba S, Oji Y, Teramoto M, Kawabata K, Saito A.

Gan To Kagaku Ryoho. 2009 Nov;36(11):1905-6. Japanese.

PMID:
19920398
20.

Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.

Ingle JN, Suman VJ, Jordan VC, Dowsett M.

Endocr Relat Cancer. 1999 Jun;6(2):265-9. Review.

Items per page

Supplemental Content

Write to the Help Desk